AdaptHealth delivered 15.9% organic revenue growth in the second quarter of fiscal 2026 (period ended June 30, 2026), yet the headline GAAP net loss of $133.9 million was dominated by a $144.2 million pre-tax non-cash goodwill impairment charge tied to the Respiratory Health and Wellness at Home reporting units, with the rest of the print dragged by a $55 million margin headwind from the full-scale ramp of the West Coast capitated partnership and a $30 million manufacturer price increase. The non-GAAP picture is more constructive: $132.0 million of adjusted EBITDA at a 17.8% margin against $136.4 million at 20.8% in the prior-year quarter, a 300 basis-point margin compression on 12.7% revenue growth that frames the next twelve months as a margin-recovery story rather than a growth story. Management cut full-year 2026 adjusted EBITDA guidance to a $490 million-to-$520 million range on a continuing-operations basis (excluding the Diabetes Health business now in discontinued operations) from the prior $680 million-to-$730 million range, and the reduction of approximately $200 million is decomposed into a $100 million divestiture reclassification, the $55 million capitated ramp drag, the $30 million manufacturer price step-up, and a $15 million portfolio actions bucket.
We see the equity at $5.81 trading at roughly 0.25x trailing enterprise value to sales, or 5.9x trailing enterprise value to the lower end of the new adjusted EBITDA guide, which is a meaningful discount to the 8-10x range that pre-rate-cut home medical equipment peers have historically carried. The market appears to be pricing capitated-ramp execution risk and manufacturer price-pass-through risk rather than the underlying volume trajectory, with the 670-location platform generating $740.3 million of revenue in the quarter and a $235 million Diabetes Health divestiture on the horizon that drops non-core revenue and refocuses the equity on Sleep and Respiratory. The single load-bearing risk is whether the Sleep and Wellness at Home margin compression reverses in the second half of 2026, with management explicitly calling out the capitated-contract complexity and the manufacturer price increase as the two specific culprits.
The falsifiable clock is the third-quarter 2026 print, expected in early November 2026, which carries the first clean look at West Coast capitated contract run-rate economics and the first evidence of manufacturer-price-pass-through pricing actions. A third-quarter adjusted EBITDA margin below 16% on the new continuing-operations base would suggest the capitated ramp is structurally margin-dilutive rather than transitional, and the equity likely re-rates lower; a margin above 18% would suggest the manufacturer cost step has been passed through and the capitated unit economics stabilize, and the equity likely re-rates toward the 8x multiple band. Our monitoring is focused on both the West Coast capitated gross margin and the gross margin in the Wellness at Home segment, where adjusted EBITDA fell from $17.5 million in the prior-year quarter to $8.7 million in the current quarter on essentially flat revenue, the single largest quarter-over-quarter margin dislocation in the print.